Degludec outperforms glargine in reducing nocturnal hypoglycemia

05/21/2013 | (free registration)

Type 1 diabetes patients who took high doses of insulin degludec once daily had lower rates of nocturnal hypoglycemia during the full trial and maintenance periods than those who took insulin glargine, a meta-analysis indicated. The findings were presented at the American Association of Clinical Endocrinologists annual meeting.

View Full Article in: (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA